CN112585169A - 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 - Google Patents

融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 Download PDF

Info

Publication number
CN112585169A
CN112585169A CN201980054796.XA CN201980054796A CN112585169A CN 112585169 A CN112585169 A CN 112585169A CN 201980054796 A CN201980054796 A CN 201980054796A CN 112585169 A CN112585169 A CN 112585169A
Authority
CN
China
Prior art keywords
antibody
umy02
fusion protein
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054796.XA
Other languages
English (en)
Inventor
莫世甫
赵勇
徐伟
王志超
杨洁
顾莉蕴
丁栋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Youmai Biotechnology Co ltd
Original Assignee
Nanjing Youmai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Youmai Biotechnology Co ltd filed Critical Nanjing Youmai Biotechnology Co ltd
Publication of CN112585169A publication Critical patent/CN112585169A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

本发明提供了融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用，所述融合蛋白包含特异性结合人OX40的抗体或其抗原结合片段和人干扰素。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980054796.XA 2018-09-04 2019-09-03 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用 Pending CN112585169A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110247831 2018-09-04
CN201811024783 2018-09-04
PCT/CN2019/104217 WO2020048454A1 (zh) 2018-09-04 2019-09-03 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用

Publications (1)

Publication Number Publication Date
CN112585169A true CN112585169A (zh) 2021-03-30

Family

ID=69721450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054796.XA Pending CN112585169A (zh) 2018-09-04 2019-09-03 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用

Country Status (6)

Country Link
EP (1) EP3848397A4 (zh)
JP (1) JP7404343B2 (zh)
KR (1) KR20210056344A (zh)
CN (1) CN112585169A (zh)
AU (1) AU2019336426A1 (zh)
WO (1) WO2020048454A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114966061A (zh) * 2022-07-28 2022-08-30 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067785A1 (zh) * 2022-09-29 2024-04-04 中国科学院生物物理研究所 基于干扰素协同免疫检查点阻断抗体治疗慢性乙型肝炎

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150203560A1 (en) * 2012-08-13 2015-07-23 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
CN108218990A (zh) * 2017-12-29 2018-06-29 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO2016065409A1 (en) 2014-10-29 2016-05-06 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
WO2017134305A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Bispecific signaling agents and uses thereof
US20210198375A1 (en) * 2018-09-04 2021-07-01 Nanjing Umab-Biopharma Co., Ltd. Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150203560A1 (en) * 2012-08-13 2015-07-23 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
CN108218990A (zh) * 2017-12-29 2018-06-29 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114966061A (zh) * 2022-07-28 2022-08-30 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法
CN114966061B (zh) * 2022-07-28 2022-10-21 中国食品药品检定研究院 一种抗ox40抗体的生物活性检测方法

Also Published As

Publication number Publication date
EP3848397A4 (en) 2022-07-20
AU2019336426A1 (en) 2021-04-29
JP2021536231A (ja) 2021-12-27
KR20210056344A (ko) 2021-05-18
EP3848397A1 (en) 2021-07-14
WO2020048454A1 (zh) 2020-03-12
JP7404343B2 (ja) 2023-12-25

Similar Documents

Publication Publication Date Title
US20210269528A1 (en) Novel anti-pd-l1 antibodies
US10696745B2 (en) Anti-PD-L1 antibodies
CN108218990B (zh) 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
CN106432494B9 (zh) 新型抗-pd-1抗体
CN106432501B (zh) 新型抗pd-l1抗体
US20210198375A1 (en) Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection
CN106243225B (zh) 新型抗-pd-l1抗体
WO2020244526A1 (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
WO2022261846A1 (zh) 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用
CN112585169A (zh) 融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
CN113444180B (zh) 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
CN115052894A (zh) 靶向cd39和tgfbeta的新型缀合物分子
CN114634577A (zh) 融合蛋白及其制备用于治疗肿瘤和病毒感染的药物的应用
EP4130043A1 (en) Anti-human cd47 antibody and antigen-binding fragment thereof, and preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044100

Country of ref document: HK

CB02 Change of applicant information

Address after: 222000 No. 425-56, Comprehensive Building, Comprehensive Bonded Zone, Lianyungang Economic and Technological Development Zone, China (Jiangsu) Pilot Free Trade Zone, Lianyungang City, Jiangsu Province

Applicant after: Youmai Biotechnology (Lianyungang) Co.,Ltd.

Address before: 210042 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu 699-1

Applicant before: NANJING UMAB-BIOPHARMA Co.,Ltd.

CB02 Change of applicant information